A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer

Background: To evaluate the activity and toxicity of docetaxel in patients with metastatic esophageal cancer. Patients and methods: Eligible patients had histologically confirmed carcinoma of the esophagus with measurable metastatic sites according to Response Evaluation Criteria in Solid Tumors (RE...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2004-06, Vol.15 (6), p.955-959
Hauptverfasser:	Muro, K., Hamaguchi, T., Ohtsu, A., Boku, N., Chin, K., Hyodo, I., Fujita, H., Takiyama, W., Ohtsu, T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - secondary Aged Antineoplastic agents Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - secondary Docetaxel esophageal cancer Esophageal Neoplasms - drug therapy Esophageal Neoplasms - pathology Female Humans Male Medical sciences Middle Aged Neutropenia - chemically induced Pharmacology. Drug treatments phase II study RECIST single agent Survival Analysis Taxoids - adverse effects Taxoids - therapeutic use Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!